全文获取类型
收费全文 | 792篇 |
免费 | 109篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 58篇 |
口腔科学 | 20篇 |
临床医学 | 88篇 |
内科学 | 40篇 |
皮肤病学 | 11篇 |
神经病学 | 48篇 |
特种医学 | 18篇 |
外科学 | 21篇 |
综合类 | 254篇 |
预防医学 | 176篇 |
眼科学 | 12篇 |
药学 | 76篇 |
4篇 | |
中国医学 | 72篇 |
肿瘤学 | 6篇 |
出版年
2024年 | 3篇 |
2023年 | 5篇 |
2022年 | 20篇 |
2021年 | 32篇 |
2020年 | 23篇 |
2019年 | 27篇 |
2018年 | 29篇 |
2017年 | 27篇 |
2016年 | 25篇 |
2015年 | 18篇 |
2014年 | 48篇 |
2013年 | 66篇 |
2012年 | 43篇 |
2011年 | 71篇 |
2010年 | 60篇 |
2009年 | 39篇 |
2008年 | 68篇 |
2007年 | 53篇 |
2006年 | 45篇 |
2005年 | 50篇 |
2004年 | 29篇 |
2003年 | 36篇 |
2002年 | 17篇 |
2001年 | 24篇 |
2000年 | 13篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 3篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1982年 | 2篇 |
1977年 | 1篇 |
排序方式: 共有912条查询结果,搜索用时 15 毫秒
911.
《European journal of surgical oncology》2023,49(3):533-541
BackgroundToday, there is still debate on the impact of neoadjuvant chemotherapy (NeoChem) on liver regeneration (LivReg). The objectives of this study were to assess the impact of NeoChem and its characteristics (addition of bevacizumab, number of cycles and time from end of NeoChem) on post-hepatectomy LivReg.Material & methodsStudies reporting LivReg in patients submitted to liver resection were included. Pubmed, Scopus, Web of Science, Embase, and Cochrane databases were searched. Only studies comparing NeoChem vs no chemotherapy or comparing chemotherapy characteristics from 1990 to present were included. Two researchers individually screened the identified records registered in a predesigned database. Primary outcome was future liver remnant regeneration rate (FLR3). Bias of the studies was evaluated with the ROBINS-I tool, and quality of evidence with the GRADE system. Data was presented as mean difference or standard mean difference.ResultsEight studies with a total of 681 patients were selected. Seven were retrospective and one prospective comparative cohort studies. In patients submitted to major hepatectomy, NeoChem did not have an impact on LivReg (MD 3.12, 95% CI -2,12–8.36, p 0,24). Adding bevacizumab to standard NeoChem was associated with better FLR3 (SMD 0.45, 95% CI 0.19–0.71, p 0.0006).DiscussionThe main drawback of this review is the retrospective nature of the available studies. NeoChem does not have a negative impact on postoperative LivReg in patients submitted to liver resection. Regimens with bevacizumab seem to be associated with better postoperative LivReg rates when compared to standard NeoChem. 相似文献
912.
Pernille Dehn MEd Susan Munch Simonsen RN MEd Mette Linnet Olesen RN MPH PhD 《Scandinavian journal of caring sciences》2023,37(2):549-560